Home/Filings/4/0001209191-21-012347
4//SEC Filing

Parini Michael 4

Accession 0001209191-21-012347

CIK 0000875320other

Filed

Feb 18, 7:00 PM ET

Accepted

Feb 19, 4:18 PM ET

Size

12.1 KB

Accession

0001209191-21-012347

Insider Transaction Report

Form 4
Period: 2021-02-17
Transactions
  • Tax Payment

    Common Stock

    2021-02-17$211.75/sh6,240$1,321,32044,106 total
  • Sale

    Common Stock

    2021-02-18$210.08/sh1,007$211,55143,099 total
  • Sale

    Common Stock

    2021-02-18$211.83/sh4,666$988,39938,433 total
  • Sale

    Common Stock

    2021-02-18$212.56/sh1,952$414,91736,481 total
  • Sale

    Common Stock

    2021-02-18$213.45/sh200$42,69036,281 total
Footnotes (6)
  • [F1]Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1.
  • [F2]Open market sales reported on this line occurred at a weighted average price of $210.08 (range $209.60 to $210.54).
  • [F3]Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
  • [F4]Open market sales reported on this line occurred at a weighted average price of $211.83 (range $211.25 to $212.24).
  • [F5]Open market sales reported on this line occurred at a weighted average price of $212.56 (range $212.25 to $212.95).
  • [F6]Open market sales reported on this line occurred at a weighted average price of $213.45 (range $213.30 to $213.68).

Issuer

VERTEX PHARMACEUTICALS INC / MA

CIK 0000875320

Entity typeother

Related Parties

1
  • filerCIK 0001661567

Filing Metadata

Form type
4
Filed
Feb 18, 7:00 PM ET
Accepted
Feb 19, 4:18 PM ET
Size
12.1 KB